Xinogen Hong Kong Pharma

Xinogen is a China-based biopharmaceutical company focused on the development and commercialization of innovative therapeutics for liver diseases and oncology. The company is best known for its flagship product, Icaritin (Alcaritin), a small molecule derived from traditional Chinese medicine that was approved by the NMPA for the treatment of advanced hepatocellular carcinoma. Xinogen maintains a robust pipeline targeting various cancers and viral infections, utilizing both small molecule and biological approaches. With headquarters in Beijing and operations in Hong Kong and Suzhou, the company integrates research, clinical development, and manufacturing to address significant unmet medical needs in the Asian market.